556 related articles for article (PubMed ID: 17709605)
1. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
2. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H
Ann Hematol; 2004 Jul; 83(7):467-70. PubMed ID: 14625789
[TBL] [Abstract][Full Text] [Related]
3. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Ciepłuch H; Baran W; Hellmann A
Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079
[TBL] [Abstract][Full Text] [Related]
4. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
6. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
[TBL] [Abstract][Full Text] [Related]
7. Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma.
Cem Ar M; Soysal T; Hatemi G; Salihoglu A; Yazici H; Ulku B
Ann Hematol; 2005 Sep; 84(9):609-13. PubMed ID: 15906029
[TBL] [Abstract][Full Text] [Related]
8. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
9. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
[TBL] [Abstract][Full Text] [Related]
10. [Thalidomide treatment in multiple myeloma].
Hattori Y
Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
[No Abstract] [Full Text] [Related]
11. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide in the treatment of multiple myeloma.
Rajkumar SV
Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
[TBL] [Abstract][Full Text] [Related]
13. [Role of thalidomide in the treatment of multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
[TBL] [Abstract][Full Text] [Related]
14. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
15. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P
Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
18. Encephalopathy in a patient after long-term treatment with thalidomide.
Sohlbach K; Heinze S; Shiratori K; Sure U; Pagenstecher A; Neubauer A
J Clin Oncol; 2006 Oct; 24(30):4942-4. PubMed ID: 17050881
[No Abstract] [Full Text] [Related]
19. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
